Sanofi Improperly Listed Lantus Patent In FDA's Orange Book, Appeals Court Finds
Executive Summary
First Circuit reverses dismissal of direct purchasers' suit alleging improper listing of patent on device drive mechanism delayed competition; district court to decide if this constitutes antitrust violation.
You may also be interested in...
Possible Orange Book Revisions Back In Play With US FDA Report To Congress
Agency is setting up an internal working group to assess whether certain patent information should be included or removed from the Orange Book. PhRMA, AAM and others address therapeutic equivalence ratings and listing of device-related and REMS-related patents.
Possible Orange Book Revisions Back In Play With US FDA Report To Congress
Agency is setting up an internal working group to assess whether certain patent information should be included or removed from the Orange Book. PhRMA, AAM and others address therapeutic equivalence ratings and listing of device-related and REMS-related patents.
Sanofi Tries To Stop Lantus Biosimilar By Getting Supreme Court To Review PTAB, Again
Sanofi seeks to delay decision clearing path for Mylan's Lantus biosimilar; says it should be able to get rehearing based on Federal Circuit's ruling that PTAB judges were not constitutionally appointed.